8-K
Crescent Biopharma Announces Clinical Pipeline Updates and Trial Progress for CR-001, CR-002, and CR-003
8-K
Crescent Biopharma Reports Q2 2026 Financial Results and Pipeline Progress
8-K
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
8-K
Crescent Biopharma, Inc. Reports Preliminary Cash Position for Q2 2026
8-K
Crescent Biopharma, Inc. Announces Results of 2026 Annual General Meeting
8-K
Crescent Biopharma Reports Q1 2026 Financial Results and Pipeline Progress
